0 (0%)		11-11 15:55
Open: High: Volume: 0		Pre. Close: Low: Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	59.54	1-year :	59.66
Resists	First :	50.98	Second :	51.08
Pivot price	50.96
Supports	First :	50.83	Second :	42.29
MAs	MA(5) :	50.89	MA(20) :	50.96
	MA(100) :	50.96	MA(250) :	50.92
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	32.6	D(3) :	25.3
RSI	RSI(14): 48.2
52-week	High :	51.34	Low :	49.75

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ FLOT ] has closed above bottom band by 42.5%. Bollinger Bands are 39.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	50.98 - 51.18	51.18 - 51.35
Low:	50.32 - 50.57	50.57 - 50.79
Close:	50.48 - 50.89	50.89 - 51.24

Tue, 11 Nov 2025
How FLOT stock behaves under inflation pressure - Trend Reversal & Accurate Intraday Trade Tips - newser.com

Sat, 08 Nov 2025
Toripalimab Plus FLOT for Metastatic Gastric Cancer - Bioengineer.org

Sat, 08 Nov 2025
Toripalimab combined with FLOT chemotherapy as conversion therapy for gastric cancer with peritoneal metastasis: a single-arm, open-label, phase II trial - BMC Cancer

Tue, 28 Oct 2025
Neoadjuvant Dual ICI Blockade vs Perioperative FLOT in dMMR/MSI-H Gastroesophageal Adenocarcinoma - The ASCO Post

Mon, 27 Oct 2025
MATTERHORN Trial Confirms Overall Survival Benefit, Positioning Durvalumab Plus FLOT as New Standard in Gastric Cancer - Managed Healthcare Executive

Sat, 18 Oct 2025
Durvalumab Plus FLOT Ups Survival in Early Upper-GI Cancer - Medscape

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange:
Sector:
Industry:
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.